Market Cap
$3.9B
CELC
Celcuity Inc.
$72.10 ▼ -4.03%
Prev close $75.13Market cap$3.9B
ConsensusStrong Buy
12-mo target$159.64 (+121.4%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)43 New Institutional Positions7 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on CELC right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$4.2B
Inst. Activity
43 buys / 7 sells
Insider Activity
$0.00 buy / $322.9M sell
Insider Net $
-$322.9M
Social Sentiment
50° Neutral
SEC Reports
10
Press Releases
5
Price chart 30d -25.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Aug 26, 2026 SEC Celcuity Appoints David Gryska To Its Board Of Directors
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board Mr. G
Celcuity submitted a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib) to treat HR+/HER2-
8-K — Impact 7/10
Aug 14, 2026 Insider
Sullivan Brian F. was granted 120,000 shares
Chief Executive Officer
Aug 14, 2026 Insider
Laing Lance G. was granted 10,000 shares
Chief Science Officer
Aug 14, 2026 Insider
Jul 15, 2026 SEC Hahne Vicky was granted 16,000 shares
Chief Financial Officer
Baker Brothers affiliates (667, L.P. and Baker Brothers Life Sciences L.P.) filed Form 144 notices to sell a combined 3,
144 — Impact 6/10
Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer wi
Impact 8/10
Jul 14, 2026 Event
REVTORPYK
Original Approval — Type 1 - New Molecular Entity — VIAL
Analyst ratings buy % +6.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | Needham | MAINTAIN | Buy | 50% |
| Sep 17, 2026 | JP Morgan | INITIATE | Overweight | 55% |
| Aug 17, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 17, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Aug 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 14, 2026 | Stifel | MAINTAIN | Buy | 54% |
| Aug 14, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 15, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Jul 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 3, 2026 | Craig-Hallum | MAINTAIN | Buy | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% |
Price targets
Where 11 covering analysts think CELC trades over the next 12 months.
$159.64 +121.4% upside Strong Buy
Current$72.10 Low$134.00 Median$160.00 High$177.00 11 analysts
$134.00$177.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 4 bullish, 2 bearish, 2 mixed, 2 neutral · avg impact 5.6/10.Plus 5 press releases.
BULLISH8-K7/10
Celcuity submitted a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib)
Aug 26, 2026
BEARISH1446/10
Baker Brothers affiliates (667, L.P. and Baker Brothers Life Sciences L.P.) filed Form 144 notices t
Jul 15, 2026
BULLISHINST-CLUSTER5/10
8 institutional buyers accumulated $182.2M in CELC (net +$166.0M) while 3 sellers trimmed $14.0M in
Jun 11, 2026
MIXED8-K6/10
Celcuity closed a $500M (plus $75M over-allotment) 0.250% convertible senior notes offering on June
Jun 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Celcuity Appoints David Gryska To Its Board Of Directors
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board Mr. Gryska brings decades of strategic and financial le
Sep 30, 2026
short_volume
Short Volume: CELC — 63.4% short (0.8M / 1.3M)
Short: 797,718 | Exempt: 100 | TRF Vol: 1,257,873 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
short_volume
Short Volume: CELC — 60.4% short (0.5M / 0.8M)
Short: 488,631 | Exempt: 0 | TRF Vol: 808,828 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
ftd
FTD: CELC — 31,638 shares ($2.8M) failed to deliver
Settlement: 20260910, Price: $90.08, FTD Value: $2,849,951.04, CELCUITY INC COM
Sep 8, 2026
ftd
FTD: CELC — 31,865 shares ($3.0M) failed to deliver
Settlement: 20260908, Price: $95.70, FTD Value: $3,049,480.5, CELCUITY INC COM
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.51 | $-1.60–$-1.42 | -93.6% | -28.0% | 0↑ 2↓ | $0.0B | 2 |
| Next Q | $-0.82 | $-1.13–$-0.51 | -12.3% | -26.2% | 0↑ 2↓ | $0.0B | 2 |
| Current FY | $-4.39 | $-4.48–$-4.30 | -36.3% | -16.4% | 0↑ 2↓ | $0.0B | 2 |
| Next FY | $-0.08 | $-0.73–$0.57 | 98.2% | -108.3% | 1↑ 1↓ | $0.3B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.510 | — |
| 7d ago | $-1.180 | -0.330 |
| 30d ago | $-1.180 | -0.330 |
| 60d ago | $-1.085 | -0.425 |
| 90d ago | $-1.085 | -0.425 |
Institutional ownership
Which big funds own CELC (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.2B total value (40,557,507 shares) as of 2026-Q2. Top holders: BAKER, Avoro, RTW. Net buying activity: 43 institutions added/increased vs 7 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 7,915,792 | $828.2M | 19.5% | — |
| Avoro Capital Advisors LLC | 3,400,000 | $355.7M | 8.4% | — |
| RTW INVESTMENTS, LP | 3,304,903 | $345.8M | 8.1% | — |
| BlackRock, Inc. | 3,018,785 | $315.8M | 7.4% | — |
| STATE STREET CORP | 1,955,304 | $204.6M | 4.8% | ADD +28.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,874,137 | $196.1M | 4.6% | — |
| BANK OF AMERICA CORP /DE/ | 1,471,307 | $153.9M | 3.6% | DOUBLED +106.0% |
| MORGAN STANLEY | 1,334,545 | $139.6M | 3.3% | — |
| TORONTO DOMINION BANK | 1,258,758 | $131.7M | 3.1% | ADD +42.6% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,111,662 | $116.3M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 1,518,705 | 1,955,304 | +28.7% | $204.6M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 714,329 | 1,471,307 | +106.0% | $153.9M |
| TORONTO DOMINION BANK | ADD | 882,758 | 1,258,758 | +42.6% | $131.7M |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 428,952 | 906,595 | +111.4% | $94.8M |
| Point72 Asset Management, L.P. | DOUBLED | 280,324 | 650,916 | +132.2% | $68.1M |
| Hood River Capital Management LLC | NEW | — | 628,411 | — | $65.7M |
| FMR LLC | DOUBLED | 36,360 | 548,983 | +1409.9% | $57.4M |
| Holocene Advisors, LP | ADD | 369,979 | 533,147 | +44.1% | $55.8M |
| UBS Group AG | DOUBLED | 220,163 | 520,946 | +136.6% | $54.5M |
| FULLER & THALER ASSET MANAGEMENT, INC. | NEW | — | 514,396 | — | $53.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 31 transactions. Net -$322.9M — $0.00 bought, $322.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Sullivan Brian F. | Chief Executive Officer | AWARD | 120,000 | — | — |
| Aug 14, 2026 | Laing Lance G. | Chief Science Officer | AWARD | 10,000 | — | — |
| Aug 14, 2026 | Hahne Vicky | Chief Financial Officer | AWARD | 16,000 | — | — |
| Aug 14, 2026 | Laing Lance G. | Chief Science Officer | AWARD | 20,000 | — | — |
| Aug 14, 2026 | Hahne Vicky | Chief Financial Officer | AWARD | 10,000 | — | — |
| Aug 14, 2026 | Sullivan Brian F. | Chief Executive Officer | AWARD | 80,000 | — | — |
| Jul 14, 2026 | BAKER BROS. ADVISORS LP | SELL | 261,368 | $102.50 | $26.8M | |
| Jul 14, 2026 | BAKER BROS. ADVISORS LP | SELL | 2,838,632 | $102.50 | $291.0M | |
| Jun 10, 2026 | Buller Richard E | Director | GIFT | 12,503 | — | — |
| Jun 10, 2026 | Murphy Polly A. | Director | GIFT | 14,048 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CELC.
Shares short
11,360,367
Settlement Sep 15, 2026
Change vs prior
+6.3%
Semi-monthly cycle
Days to cover
12.5
At avg daily volume
Of shares outstanding
≈23.2%
Estimate — not % of float
All CELC filing & press-release reports (15)
- 8-K reportAug 26, 2026
- 144 reportJul 15, 2026
- PRESS-RELEASE reportJul 14, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 8, 2026
- 424B5 reportJun 5, 2026
- PRESS-RELEASE reportJun 4, 2026
- PRESS-RELEASE reportJun 3, 2026
- 424B5 reportJun 3, 2026
- 8-K reportJun 2, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMay 7, 2026
- 144 reportMay 4, 2026
- PRESS-RELEASE reportMay 1, 2026
- PRESS-RELEASE reportMar 25, 2026